Zobrazeno 1 - 10
of 141
pro vyhledávání: '"Abby B, Siegel"'
Autor:
Philippe Merle, Masatoshi Kudo, Julien Edeline, Mohamed Bouattour, Ann-Lii Cheng, Stephen Lam Chan, Thomas Yau, Marcelo Garrido, Jennifer Knox, Bruno Daniele, Valeriy Breder, Ho Yeong Lim, Sadahisa Ogasawara, Stéphane Cattan, Yee Chao, Abby B. Siegel, Iván Martinez-Forero, Ziwen Wei, Chih-Chin Liu, Richard S. Finn
Publikováno v:
Liver Cancer (2023)
Introduction: KEYNOTE-240 showed a favorable benefit/risk profile for pembrolizumab versus placebo in patients with sorafenib-treated advanced hepatocellular carcinoma (HCC); however, prespecified statistical significance criteria for overall surviva
Externí odkaz:
https://doaj.org/article/cd768b0d783a455fbb086706dc35b886
Autor:
Masatoshi Kudo, Ho Yeong Lim, Ann-Lii Cheng, Yee Chao, Thomas Yau, Sadahisa Ogasawara, Masayuki Kurosaki, Naoki Morimoto, Kazuyoshi Ohkawa, Tatsuya Yamashita, Kyung-Hun Lee, Erluo Chen, Abby B. Siegel, Baek-Yeol Ryoo
Publikováno v:
Liver Cancer, Vol 10, Iss 3, Pp 275-284 (2021)
Introduction: KEYNOTE-240 investigated the efficacy and safety of pembrolizumab plus best supportive care (BSC) in sorafenib-treated patients with advanced hepatocellular carcinoma (HCC). Results for the subgroup of patients from Asia are described.
Externí odkaz:
https://doaj.org/article/6811a292141f4067ae7851205840ec6a
Autor:
Arndt Vogel, Philippe Merle, Chris Verslype, Richard S. Finn, Andrew X. Zhu, Ann-Lii Cheng, Stephen Lam Chan, Thomas Yau, Baek-Yeol Ryoo, Jennifer Knox, Bruno Daniele, Shukui Qin, Ziwen Wei, Yanna Miteva, Usha Malhotra, Abby B. Siegel, Masatoshi Kudo
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Aims: This post hoc analysis evaluated albumin/bilirubin (ALBI) score, an objective measure of liver function, in patients receiving pembrolizumab plus best supportive care (BSC) compared with placebo plus BSC in the KEYNOTE-240 study. Methods: Patie
Externí odkaz:
https://doaj.org/article/791d73efce4141ad860d27a8dbc5489c
Autor:
Josep M. Llovet, Arndt Vogel, David C. Madoff, Richard S. Finn, Sadahisa Ogasawara, Zhenggang Ren, Kalgi Mody, Jerry J. Li, Abby B. Siegel, Leonid Dubrovsky, Masatoshi Kudo
Publikováno v:
CardioVascular and Interventional Radiology. 45:405-412
Purpose Transarterial chemoembolization (TACE) is the standard of care for patients with intermediate-stage hepatocellular carcinoma (HCC). Lenvatinib, a multikinase inhibitor, and pembrolizumab, a PD-1 inhibitor, have shown efficacy and tolerability
Autor:
Robin Kate Kelley, Makoto Ueno, Changhoon Yoo, Richard S Finn, Junji Furuse, Zhenggang Ren, Thomas Yau, Heinz-Josef Klümpen, Stephen L Chan, Masato Ozaka, Chris Verslype, Mohamed Bouattour, Joon Oh Park, Olga Barajas, Uwe Pelzer, Juan W Valle, Li Yu, Usha Malhotra, Abby B Siegel, Julien Edeline, Arndt Vogel, Mehmet Akce, Immaculada Ales Diaz, Gustavo Alves, Sumitra Anand, Cagatay Arslan, Jamil Asselah, Eric Assenat, Francine Aubin, Li-Yuan Bai, Yuxian Bai, Susan Bates, Stephen Begbie, Irit Ben-Aharon, Nina Beri, Marie-Luise Berres, Jean-Frederic Blanc, Ivan Borbath, Robert Bordonaro, Giovanni Brandi, Adam Burgoyne, Kritiya Butthongkomvong, Ke Cao, Marcela Carballido, Marcos Camandaroba, Stephan Lam Chang, Jen-Shi Chen, Ming-Huang Chen, Xiaoming Chen, Ashley Cheng, Tai-Jan Chiu, Hye Jin Choi, Hong Jae Chon, Joelle Collignon, Antonio Cubillo Gracian, Sarah Davis, Ricardo Saraiva de Carvalho, D.J.A. de Groot, Anne Demols, Judith De Vos, Maria Diab, Jacob Easaw, Martin Eatock, Rawad Elias, Fredericus Eskens, Alfredo Falcone, Plinio Fernandez, Richard Finn, Fabio Franke, Masayuki Furukawa, Olumide Gbolahan, Karen Geboes, Keri-Lee Geneser, Zhimin Geng, Ravit Geva, Roopinder Gillmore, Thorsten Goetze, Hongfeng Gou, Julieta Grasselli, Shanzhi Gu, Mahmut Gumus, Nadia Haj Mohammad, Chunyi Hao, Hakan Harputluoglu, Hassan Hatoum, Volker Heinemann, Wang Kwong Ho, Chiun Hsu, Ayala Hubert, Juneul Hwang, Mevlude Inanc, Soledad Iseas, Vaishnavi Jeyasingam, Paula Jimenez Fonseca, Warren Joubert, Jitlada Juengsamarn, Diego Kaen, Masahi Kanai, Stefan Kasper-Virchow, Ghazaleh Kazemi, Fergal Kelleher, Robin Kelley, Jin Won Kim, Jong Gwang Kim, Ana Beatriz Kinupe Abrahao, Heinz Klumpen, Mark Kochenderfer, Fatih Kose, Ho Ching Lam, Choong-kun Lee, Hyun Woo Lee, Margaret Lee, Myung Ah Lee, Wai Man Sarah Lee, Samuel Le Sourd, Dongliang Li, Wei Li, Houjie Liang, Tingbo Liang, Chun Sen Lim, Brian Lingerfelt, Charles Lopez, John Low, Teresa Macarulla Mercade, David Malka, Yimin Mao, Gianluca Masi, Steven McCune, Ray McDermott, Elaine McWhirter, Guillermo Mendez, Michele Milella, Tomonori Mizutani, Camila Moniz, Luisa Morales, Andres Jesús Munoz Martin, Bruno Nervi, Nuttapong Ngamphaiboon, Sang Cheul Oh, Berna Oksuzoglu, Darryl Outlaw, Mustafa Ozguroglu, Ozgur Ozyilkan, Claudio Painemeal, Yueyin Pan, Chuang Peng, Caroline Petorin, Denis Pezet, Derek Power, Shukui Qin, Aflah Roohullah, Hyewon Ryu, Pamela Salman, Rita Sasidharan, Taroh Satho, Kornelius Schulze, Martin Scott-Brown, Ruben Segovia, Thomas Seufferlin, Salvatore Siena, Isabelle Sinapi, Cristina Smolenschi, Tianqiang Song, Aumkhae Sookprasert, Nopadol Soparattanapaisarn, Naureen Starling, Stacey Stein, Salomon Stemmer, Haichuan Su, Rie Sugimoto, Thatthan Suksombooncharoen, Vincent Tam, Ai Lian Tan, Chih Kiang Tan, Suebpong Tanasanvimon, Giuseppe Tonini, Giampaolo Tortora, Akihito Tsuji, Rodrigo Uribe, Marino Venerito, Helena Verdaguer Mata, Ana Paula Victorino, James Wade, Dirk Thomas Waldschmidt, Lu Wang, Wan Zamaniah Wan Isahk, Harpeet Wasan, Rui Weschenfelder, Chun Yin Wong, Yoke Fui Wong, Suayib Yalcin, Patricio Yanez Weber, Xuezhong Yang, Hisateru Yasui, Ozan Yazici, Chia-Jui Yen, Jieer Ying, Wenchang Yu, Haitao Zhao
Publikováno v:
The KEYNOTE-966 Investigators, Kelley, R K, Ueno, M, Yoo, C, Finn, R S, Furuse, J, Ren, Z, Yau, T, Klümpen, H-J, Chan, S L, Ozaka, M, Verslype, C, Bouattour, M, Park, J O, Barajas, O, Pelzer, U, Valle, J W, Yu, L, Malhotra, U, Siegel, A B, Edeline, J & Vogel, A 2023, ' Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial ', The Lancet . https://doi.org/10.1016/S0140-6736(23)00727-4
The Lancet
The Lancet, 2023, 401 (10391), pp.1853-1865. ⟨10.1016/S0140-6736(23)00727-4⟩
KEYNOTE-966 Investigators 2023, ' Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966) : a randomised, double-blind, placebo-controlled, phase 3 trial ', The Lancet, vol. 401, no. 10391, pp. 1853-1865 . https://doi.org/10.1016/S0140-6736(23)00727-4
The Lancet, 401(10391), 1853-1865. Elsevier Limited
The Lancet
The Lancet, 2023, 401 (10391), pp.1853-1865. ⟨10.1016/S0140-6736(23)00727-4⟩
KEYNOTE-966 Investigators 2023, ' Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966) : a randomised, double-blind, placebo-controlled, phase 3 trial ', The Lancet, vol. 401, no. 10391, pp. 1853-1865 . https://doi.org/10.1016/S0140-6736(23)00727-4
The Lancet, 401(10391), 1853-1865. Elsevier Limited
Background: Biliary tract cancers, which arise from the intrahepatic or extrahepatic bile ducts and the gallbladder, generally have a poor prognosis and are rising in incidence worldwide. The standard-of-care treatment for advanced biliary tract canc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67e2bc96e0f72cde5bf243ad704e6b14
https://pure.manchester.ac.uk/ws/files/261634672/Pembrolizumab_in_combination_with_gemcitabine_and_cisplatin_compared_with_gemcitabine_and_cisplatin_alone_for_advanced_biliary...28Mar2023.docx
https://pure.manchester.ac.uk/ws/files/261634672/Pembrolizumab_in_combination_with_gemcitabine_and_cisplatin_compared_with_gemcitabine_and_cisplatin_alone_for_advanced_biliary...28Mar2023.docx
Autor:
Andrew X. Zhu, Richard S. Finn, Anran Wang, Ken Hatogai, Michael Chisamore, Abby B. Siegel, Shukui Qin, Jennifer J. Knox, Stephen L. Chan, Bruno Daniele, Sadahisa Ogasawara, Ann-Lii Cheng, Masatoshi Kudo, Stephane Cattan, Julien Edeline, Arndt Vogel, Daniel H. Palmer, Debashis Sarker, Per Stal, Vittorina Zagonel, Adel Kardosh, Hans Van Vlierberghe, Chris Verslype, Mark Karwal, Ivan Borbath, Gontran Verset
Supplementary Data from Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f878324f4138a41d0d21b069afb2bed
https://doi.org/10.1158/1078-0432.22487754.v1
https://doi.org/10.1158/1078-0432.22487754.v1
Editorial from Serum Antioxidant Nutrients, Vitamin A, and Mortality in U.S. Adults
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e171ac640cdf97c390af420c5c8c1be2
https://doi.org/10.1158/1055-9965.22437511.v1
https://doi.org/10.1158/1055-9965.22437511.v1
Autor:
Andrew X. Zhu, Richard S. Finn, Anran Wang, Ken Hatogai, Michael Chisamore, Abby B. Siegel, Shukui Qin, Jennifer J. Knox, Stephen L. Chan, Bruno Daniele, Sadahisa Ogasawara, Ann-Lii Cheng, Masatoshi Kudo, Stephane Cattan, Julien Edeline, Arndt Vogel, Daniel H. Palmer, Debashis Sarker, Per Stal, Vittorina Zagonel, Adel Kardosh, Hans Van Vlierberghe, Chris Verslype, Mark Karwal, Ivan Borbath, Gontran Verset
Supplementary Table from Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::baebad0607bff4283e57c19482ca76af
https://doi.org/10.1158/1078-0432.22487739.v1
https://doi.org/10.1158/1078-0432.22487739.v1
Background: Observational studies have suggested that antioxidant nutrients may reduce cancer and overall mortality risks. However, most randomized trials have failed to show survival benefits. Examining nonlinear associations between antioxidant lev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ccda5194a29e96815a4be5e7ab543b7
https://doi.org/10.1158/1055-9965.c.6515911.v1
https://doi.org/10.1158/1055-9965.c.6515911.v1
PDF - 304 KB, Table S1. Hazard Ratios Additionally Adjusted for Serum C-reactive Protein Levels Table S2. Hazard Ratios Additionally Adjusted for Serum Levels of Other Micronutrients in the study Table S3. Hazard Ratios after Excluding NHANES III Par
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af54be3c428c24bb4d6cc98da5ce6248
https://doi.org/10.1158/1055-9965.22437508
https://doi.org/10.1158/1055-9965.22437508